B-cell maturation antigen (BCMA)-targeted CAR NK cells

N/A

Report date: 2025/01/26 19:25:48

Base Information

Drug NameB-cell maturation antigen (BCMA)-targeted CAR NK cells
Drug Alias Nameanti-BCMA CAR NK-cell therapy (MD Anderson/Takeda)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulators
TargetsTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsHematologic NeoplasmsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer CenterTakeda Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A